Journal articles: 'Adjuvant therapies'

1

Castiglione, M. "63 Tailored adjuvant therapies." European Journal of Cancer Supplements 1, no. 5 (September 2003): S24. http://dx.doi.org/10.1016/s1359-6349(03)90098-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Seya, Tsukasa, Takashi Akazawa, Tadayuki Tsujita, and Misako Matsumoto. "Role of Toll-like Receptors in Adjuvant-Augmented Immune Therapies." Evidence-Based Complementary and Alternative Medicine 3, no. 1 (2006): 31–38. http://dx.doi.org/10.1093/ecam/nek010.

Full text

Abstract:

Effective therapeutic vaccines contain two primary constituents, antigen and adjuvant. Adjuvants consisting of microbial pattern molecules play a central role in vaccination. Successful vaccine requires efficient induction of antibody (Ab), type I interferons (IFN), cytokines/chemokines, cytotoxic T lymphocytes (CTL) and/or NK cells. Toll-like receptors (TLRs) in myeloid dendritic cells (mDC) essentially act as adjuvant receptors and sustain the molecular basis of adjuvant activity. Current consensus is that TLRs and their adapters introduce signals to preferentially induce IFN-α/β, chemokines and proinflammatory cytokines, and mature mDC to augment antigen presentation. Although most of these data were obtained with mice, the results are presumed to be adaptable to humans. Whenever TLR pathway is activated in mDC, NK and/or CTL activation is promoted. For induction of antigen-specific CTL toward phagocytosed material, cross-priming must be induced in mDC, which is also sustained by TLR signaling in mDC. Since the TLR responses vary with different adjuvants, mDC functions are skewed depending on adjuvant-specific direction of mDC maturation. It appears that the directed maturation of mDC largely relies on selection of appropriate sets of TLRs and their adapter signaling pathways. Synthetic chimera molecules consisting of TLR agonists and target antigens are found to be effective in induction of CTL to eliminate target cellsin vivo. Here, we review the role of human TLRs and adapters in a variety of host immune responses. We will also describe the relevance of adjuvants in the manipulation of receptors and adapters in vaccine therapy.

APA, Harvard, Vancouver, ISO, and other styles

3

Kosmider, Suzanne. "Adjuvant therapies for colorectal cancer." World Journal of Gastroenterology 13, no. 28 (2007): 3799. http://dx.doi.org/10.3748/wjg.v13.i28.3799.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Abdelhakeem, Ahmed, and Mariela Blum Murphy. "Adjuvant Therapies for Esophageal Cancer." Thoracic Surgery Clinics 32, no. 4 (November 2022): 457–65. http://dx.doi.org/10.1016/j.thorsurg.2022.06.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ponzio, Humberto Antônio. "Combined strategies and adjuvant therapies." Expert Review of Dermatology 1, no. 1 (February 2006): 177–80. http://dx.doi.org/10.1586/17469872.1.1.177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Carina, Valeria, Viviana Costa, Maria Sartori, Daniele Bellavia, Angela De Luca, Lavinia Raimondi, Milena Fini, and Gianluca Giavaresi. "Adjuvant Biophysical Therapies in Osteosarcoma." Cancers 11, no. 3 (March 12, 2019): 348. http://dx.doi.org/10.3390/cancers11030348.

Full text

Abstract:

Osteosarcoma (OS) is a primary bone sarcoma, manifesting as osteogenesis by malignant cells. Nowadays, patients’ quality of life has been improved, however continuing high rates of limb amputation, pulmonary metastasis and drug toxicity, remain unresolved issues. Thus, effective osteosarcoma therapies are still required. Recently, the potentialities of biophysical treatments in osteosarcoma have been evaluated and seem to offer a promising future, thanks in this field as they are less invasive. Several approaches have been investigated such as hyperthermia (HT), high intensity focused ultrasound (HIFU), low intensity pulsed ultrasound (LIPUS) and sono- and photodynamic therapies (SDT, PDT). This review aims to summarize in vitro and in vivo studies and clinical trials employing biophysical stimuli in osteosarcoma treatment. The findings underscore how the technological development of biophysical therapies might represent an adjuvant role and, in some cases, alternative role to the surgery, radio and chemotherapy treatment of OS. Among them, the most promising are HIFU and HT, which are already employed in OS patient treatment, while LIPUS/SDT and PDT seem to be particularly interesting for their low toxicity.

APA, Harvard, Vancouver, ISO, and other styles

7

Romero, Diana. "Avoiding overuse of adjuvant therapies." Nature Reviews Clinical Oncology 15, no. 8 (June 19, 2018): 469. http://dx.doi.org/10.1038/s41571-018-0054-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kronowitz, Steven J., and Geoffrey L. Robb. "Breast Reconstruction and Adjuvant Therapies." Seminars in Plastic Surgery 18, no. 2 (May 2004): 105–15. http://dx.doi.org/10.1055/s-2004-829045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Loh, Wenyin, and Mimi Tang. "Adjuvant Therapies in Food Immunotherapy." Immunology and Allergy Clinics of North America 38, no. 1 (February 2018): 89–101. http://dx.doi.org/10.1016/j.iac.2017.09.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Singhi, S. "Effective Adjuvant Therapies for Meningitis." International Journal of Infectious Diseases 14 (March 2010): e331-e332. http://dx.doi.org/10.1016/j.ijid.2010.02.2230.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Olofsson Bagge, R., and L. Ny. "Adjuvant therapies for malignant melanoma." British Journal of Surgery 103, no. 9 (June 1, 2016): 1095–96. http://dx.doi.org/10.1002/bjs.10202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Stănescu, Ana Maria Alexandra, Ioana Veronica Grăjdeanu, Constantin Ştefani, Adela Mihaela Iancu, Cristina Olariu, Cristian Paparău, and Camelia Cristina Diaconu. "Adjuvant therapies to improve the results of pharmacological therapies in rosacea." Romanian Medical Journal 65, no. 4 (December 31, 2018): 253–57. http://dx.doi.org/10.37897/rmj.2018.4.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Yechieli, Raphael, Steven Bialick, Crystal Seldon, and Emily Jonczak. "Adjuvant Therapies in Metastatic Bone Disease." Operative Techniques in Orthopaedics 31, no. 3 (September 2021): 100899. http://dx.doi.org/10.1016/j.oto.2021.100899.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Lang, Cassie, and Mary Beth Flynn Makic. "Managing Postoperative Pain: Rethinking Adjuvant Therapies." Journal of PeriAnesthesia Nursing 35, no. 2 (April 2020): 212–14. http://dx.doi.org/10.1016/j.jopan.2020.01.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Lim, Kok Haw Jonathan, and Teresa Amaral. "Adjuvant and neoadjuvant therapies in melanoma." ESMO Open 5, no. 4 (July 2020): e000849. http://dx.doi.org/10.1136/esmoopen-2020-000849.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Hernandez-Aya, Leonel F., and Ana M. Gonzalez-Angulo. "Adjuvant Systemic Therapies in Breast Cancer." Surgical Clinics of North America 93, no. 2 (April 2013): 473–91. http://dx.doi.org/10.1016/j.suc.2012.12.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Hilbe, Wolfgang, and Eberhard Gunsilius. "Are adjuvant therapies beyond all doubt?" memo - Magazine of European Medical Oncology 1, no. 2 (June 2008): 53. http://dx.doi.org/10.1007/s12254-008-0034-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Rodríguez Sánchez, C. A. "Adjuvant endocrine therapies for premenopausal women." Clinical and Translational Oncology 9, no. 6 (June 2007): 369–74. http://dx.doi.org/10.1007/s12094-007-0069-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Adjuvant therapies beneficial for cervical cancer." Inpharma Weekly &NA;, no. 1579 (March 2007): 13. http://dx.doi.org/10.2165/00128413-200715790-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Rathnayake, Wasantha. "Adjuvant therapies for large bowel cancer." Sri Lanka Journal of Surgery 31, no. 2 (August 18, 2013): 1. http://dx.doi.org/10.4038/sljs.v31i2.5952.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Thomsen, James, and Verlia Gower. "Adjuvant Therapies in Children Undergoing Adenotonsillectomy." Laryngoscope 112, S100 (October 20, 2009): 32–34. http://dx.doi.org/10.1002/lary.5541121412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Buti, Sebastiano, Melissa Bersanelli, Maddalena Donini, and Andrea Ardizzoni. "Systemic adjuvant therapies in renal cell carcinoma." Oncology Reviews 6, no. 2 (October 8, 2012): 18. http://dx.doi.org/10.4081/oncol.2012.e18.

Full text

Abstract:

Renal cell carcinoma (RCC) is one of the ten most frequent solid tumors worldwide. Recent innovations in the treatment of metastatic disease have led to new therapeutic approaches being investigated in the adjuvant setting. Observation is the only current standard of care after radical nephrectomy, although there is evidence of efficacy of adjuvant use of vaccine among all the strategies used. This article aims to collect published experiences with systemic adjuvant approaches in RCC and to describe the results of past and ongoing phase III clinical trials in this field. We explored all the systemic treatments, including chemotherapy, immunotherapy and targeted drugs while alternative approaches have also been described. Appropriate selection of patients who would benefit from adjuvant therapies remains a crucial dilemma. Although the international guidelines do not actually recommend any adjuvant treatment after radical surgery for RCC, no conclusions have yet been drawn pending the results of the promising ongoing clinical trials with the target therapies. The significant changes that these new drugs have made on advanced disease outcome could represent the key to innovation in terms of preventing recurrence, delaying relapse and prolonging survival after radical surgery for RCC.

APA, Harvard, Vancouver, ISO, and other styles

23

Ponto, Jay, and R. Bryan Bell. "Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma." Oral and Maxillofacial Surgery Clinics of North America 34, no. 2 (May 2022): 315–24. http://dx.doi.org/10.1016/j.coms.2021.11.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Burgos-Alonso, Natalia, Igone Lobato, Igone Hernández, Kepa Sebastian, Begoña Rodríguez, Gontzal Grandes, and Isabel Andia. "Adjuvant Biological Therapies in Chronic Leg Ulcers." International Journal of Molecular Sciences 18, no. 12 (November 28, 2017): 2561. http://dx.doi.org/10.3390/ijms18122561.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Dhiwakar, M., and P. M. Brown. "Are adjuvant therapies for tonsillectomy evidence based?" Journal of Laryngology & Otology 119, no. 8 (August 2005): 614–19. http://dx.doi.org/10.1258/0022215054516223.

Full text

Abstract:

Our aim was to ascertain the current practice of adjuvant therapy for tonsillectomy and to determine whether it is evidence based. Anonymized postal questionnaires were sent to all UK otolaryngology consultants registered with the specialty association, and a literature search was performed using relevant search terms in all possible combinations. Among the responders there was little enthusiasm for routine intra-operative local anaesthesia, post-operative topical benzydamine hydrochloride (Difflam) spray or post-operative antibiotics. This is consistent with the lack of robust evidence to support any of these practices. Paracetamol (acetaminophen) is prescribed by almost 90 per cent for post-operative analgesia, and the current literature supports its efficacy and safety. Further, most practitioners combine paracetamol with opioids and/or non-steroidal anti-inflammatory drugs (NSAIDs). Evidence to support the additional use of these agents is, however, non-existent or limited. Some aspects of tonsillectomy care are uniform and evidence based. Others are heterogeneous and suffer from lack of adequate data in the literature.

APA, Harvard, Vancouver, ISO, and other styles

26

Chun, Yun Shin, and Milind Javle. "Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma." Cancer Control 24, no. 3 (September 2017): 107327481772924. http://dx.doi.org/10.1177/1073274817729241.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pantel, K. "Micrometastatic cells as targets for adjuvant therapies." European Journal of Cancer Supplements 2, no. 3 (March 2004): 68. http://dx.doi.org/10.1016/s1359-6349(04)90644-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Pritchard, K. "S23 Adjuvant Endocrine Therapies for Pre/PerimenopausalWomen." Breast 14 (February 2005): S9. http://dx.doi.org/10.1016/s0960-9776(05)80024-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Partridge, A. "S38 Adjuvant therapies for the very young." Breast 20 (March 2011): S14—S15. http://dx.doi.org/10.1016/s0960-9776(11)70040-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Wolchok, Jedd D., Philip O. Livingston, and Alan N. Houghton. "VACCINES AND OTHER ADJUVANT THERAPIES FOR MELANOMA." Hematology/Oncology Clinics of North America 12, no. 4 (August 1998): 835–48. http://dx.doi.org/10.1016/s0889-8588(05)70026-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Schutz, Fabio A. B., and William K. Oh. "Neoadjuvant and Adjuvant Therapies in Prostate Cancer." Urologic Clinics of North America 37, no. 1 (February 2010): 97–104. http://dx.doi.org/10.1016/j.ucl.2009.11.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Pritchard, Kathleen I. "Adjuvant endocrine therapies for pre-/perimenopausal women." Breast 14, no. 6 (December 2005): 547–54. http://dx.doi.org/10.1016/j.breast.2005.09.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Goldhirsch, Aron. "Personalized adjuvant therapies: Lessons from the past." Breast 22 (August 2013): S3—S7. http://dx.doi.org/10.1016/j.breast.2013.07.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Messika, Jonathan, Pierre Kalfon, and Jean-Damien Ricard. "Adjuvant therapies in critical care: music therapy." Intensive Care Medicine 44, no. 11 (January 20, 2018): 1929–31. http://dx.doi.org/10.1007/s00134-018-5056-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Apuri, Susmitha. "Neoadjuvant and Adjuvant Therapies for Breast Cancer." Southern Medical Journal 110, no. 10 (October 2017): 638–42. http://dx.doi.org/10.14423/smj.0000000000000703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Govaerts, Dries, Frederik Piccart, Anna Ockerman, Ruxandra Coropciuc, Constantinus Politis, and Reinhilde Jacobs. "Adjuvant therapies for MRONJ: A systematic review." Bone 141 (December 2020): 115676. http://dx.doi.org/10.1016/j.bone.2020.115676.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ciuman, Raphael Richard. "Phytotherapeutic and naturopathic adjuvant therapies in otorhinolaryngology." European Archives of Oto-Rhino-Laryngology 269, no. 2 (September 16, 2011): 389–97. http://dx.doi.org/10.1007/s00405-011-1755-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

McGuire, Jennifer L., Jeffrey S. Barrett, Heather E. Vezina, Sergei Spitsin, and Steven D. Douglas. "Adjuvant therapies for HIV ‐associated neurocognitive disorders." Annals of Clinical and Translational Neurology 1, no. 11 (October 23, 2014): 938–52. http://dx.doi.org/10.1002/acn3.131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Möbus, Volker, Susanne Hell, and Marcus Schmidt. "Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer." Geburtshilfe und Frauenheilkunde 77, no. 10 (October 2017): 1079–87. http://dx.doi.org/10.1055/s-0043-119542.

Full text

Abstract:

AbstractOncologic therapy is currently undergoing significant changes. A number of innovative targeted medications currently in clinical development have raised high expectations. With that in mind, discussions about terms such as “clinical benefit” and “clinical relevance” are highly topical. This also applies to further developments in the field of adjuvant systemic therapies for early-stage breast cancer. As the treatment aim is curative, assessment of the clinical benefit of adjuvant therapies must be largely based on efficacy outcomes. The focus must be on improving disease-free survival rates and lowering the risk of recurrence. Because of the current low mortality rates, statements about overall survival rates are only possible after very long observation periods. Consequently, new drugs in adjuvant therapies should be considered as offering a clinical benefit, if they reduce the risk of recurrence below current low levels of risk. The evidence for established adjuvant therapy standards in early-stage breast cancer can be used as objective criteria for comparison. This review article considers the requirements for clinical benefit of new adjuvant therapies for early breast cancer, based on examples from adjuvant endocrine therapy, adjuvant polychemotherapy and adjuvant anti-HER2 therapy.

APA, Harvard, Vancouver, ISO, and other styles

40

Wang, Jun, Xiao Dong He, Nan Yao, Wen Jia Liang, and You Cheng Zhang. "A Meta-Analysis of Adjuvant Therapy after Potentially Curative Treatment for Hepatocellular Carcinoma." Canadian Journal of Gastroenterology 27, no. 6 (2013): 351–63. http://dx.doi.org/10.1155/2013/417894.

Full text

Abstract:

BACKGROUND: The high recurrence rate of hepatocellular carcinoma (HCC) after potentially curative treatment determines the long-term prognosis.OBJECTIVE: To evaluate the efficacy and safety of adjuvant therapies in patients with HCC who have undergone hepatic resection, transplantation or locoregional ablation therapy.METHODS: Several databases were searched to identify randomized controlled trials (RCTs) fulfilling the predefined selection criteria. Meta-analyses were performed to estimate the effects of adjuvant therapies of any modality on recurrence-free survival (RFS) and overall survival (OS).RESULTS: Eight adjuvant modalities were identified from 27 eligible RCTs conducted predominantly in Asian populations comparing adjuvant with no adjuvant therapy. Adjuvant chemotherapy, internal radiation and heparanase inhibitor PI-88 therapy failed to improve RFS or OS, while interferon (IFN) therapy yielded significant survival results. The findings of adjuvant vitamin analogue therapy required further examination. Adjuvant adoptive immunotherapy conferred significant benefit for RFS but not for OS. Although cancer vaccine therapy and radioimmunotherapy may improve survival after radical surgery, the results were from single, small-scale trials. Severe side effects were observed in the studies of adjuvant chemotherapy and of IFN therapy.CONCLUSIONS: Adjuvant IFN therapy can improve both RFS and OS; however, the benefits of using this agent should be weighed against its side effects. Combination of systemic and transhepatic arterial chemotherapy is not recommended for HCC after potentially curative treatment. Other adjuvant therapies produce limited success for survival. Additional RCTs with proper design are required to establish the role of adjuvant therapies for HCC.

APA, Harvard, Vancouver, ISO, and other styles

41

Tozuka, Takehiro, Rintaro Noro, Masahiro Seike, and Kazufumi Honda. "Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability." Cancers 14, no. 18 (September 7, 2022): 4363. http://dx.doi.org/10.3390/cancers14184363.

Full text

Abstract:

Surgical treatment is the best curative treatment option for patients with non-small cell lung cancer (NSCLC), but some patients have recurrence beyond the surgical margin even after receiving curative surgery. Therefore, therapies with anti-cancer agents also play an important role perioperatively. In this paper, we review the current status of adjuvant chemotherapy in NSCLC and describe promising perioperative therapies, including molecularly targeted therapies and immune checkpoint inhibitors. Previously reported biomarkers of adjuvant chemotherapy for NSCLC are discussed along with their limitations. Adjuvant chemotherapy after resective surgery was most effective in patients with metastatic lesions located just outside the surgical margin; in addition, these metastatic lesions were the most sensitive to adjuvant chemotherapy. Thus, the first step in predicting patients who have sensitivity to adjuvant therapies is to perform a qualified evaluation of metastatic ability using markers such as actinin-4 (ACTN4). In this review, we discuss the potential use of biomarkers in patient stratification for effective adjuvant chemotherapy and, in particular, the use of ACTN4 as a possible biomarker for NSCLC.

APA, Harvard, Vancouver, ISO, and other styles

42

Schuster, James M., and M. Sean Grady. "Medical management and adjuvant therapies in spinal metastatic disease." Neurosurgical Focus 11, no. 6 (December 2001): 1–3. http://dx.doi.org/10.3171/foc.2001.11.6.4.

Full text

Abstract:

Metastatic spinal tumors are an increasingly common and difficult problem encountered by neurosurgeons and orthopedic surgeons. To improve therapies and increase life expectancy for patients with tumors such as those of the breast and prostate, a global, systematic approach is required to maximize the preservation of neurological function, maintenance of spinal stability, and relief of pain, all with the ultimate goal of improved functional capacity and quality of life (QOL). Although radiotherapy and surgery are still the primary therapeutic options, several new adjuvant therapies initially implemented to control pain more effectively have also been shown to reduce overall skeleton-related complications (pathological fractures and hypercalcemia) and may ultimately improve and extend QOL. This more global approach to spinal metastases also includes optimizing each patient's overall medical condition and potential for healing (that is, nutrition), as well as avoiding potential complications associated with metastatic disease (such as deep vein thrombosis), including excessive blood loss in the case of renal metastasis. A thorough knowledge and understanding of these therapeutic adjuvants is required to optimize care and to respond to our increasingly medically knowledgable patient population whose access to prevalent medical information has been increased because of the internet.

APA, Harvard, Vancouver, ISO, and other styles

43

Dover, Laura, Rojymon Jacob, Thomas Wang, Robert Oster, and Derek Dubay. "Impact of adjuvant therapies on survival in patients with cholangiocarcinoma." Journal of Clinical Oncology 32, no. 3_suppl (January 20, 2014): 360. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.360.

Full text

Abstract:

360 Background: Surgical resection is the only curative option for Cholangiocarcinoma (CC) and currently there are no clear guidelines for adjuvant therapy following resection. Given the high incidence of local and distant recurrences following resection, we evaluated the impact of adjuvant chemotherapy or chemoradiation (CRT) on median survival (OS). Methods: A retrospective review was performed identifying all patients with CC who underwent curative surgical resection at our institution between 2002 and 2012. Patients who underwent aborted or palliative procedures were excluded. Survival estimates were quantified using Kaplan Meier curves, and differences between groups were compared with the log-rank test and Cox regression models. Results: During the study period, 103 patients underwent curative resection for CC at our institution. Tumor location was intrahepatic, perihilar and distal in 37% (n=38), 23% (n=24) and 40% (n=41) respectively. A total of 49 (48%) patients received adjuvant chemotherapy (n= 28) or CRT (n=21). Observation with no additional therapy was employed in the remaining 54 (52%) patients. No patient was treated using radiation alone. OS was 21.4 and 41.4 months (m) for those receiving adjuvant therapy versus observation (p=0.08). OS for adjuvant therapy versus observation were 28.4 m and 19.4 m respectively, if surgical margins were positive (p=0.036); and 79.1 m and 26.3 m respectively (p=0.4) with negative resection margins. OS was 41.4 m and 38.0 m with adjuvant chemo versus CRT respectively (p=0.1). Tumor stage was the only statistically significant pathologic indicator of outcome (p=0.019). Conclusions: A trend towards significant improvement in OS was observed with the use of adjuvant therapy among all patients following resection of CC. Adjuvant therapy significantly improved OS among CC patients with positive margins of resection. The small number of patients with negative margins of resection also benefitted, though not significantly. These data suggest that while adjuvant therapy should be considered for all patients irrespective of margin status; patients with positive margins are likely to benefit the most.

APA, Harvard, Vancouver, ISO, and other styles

44

Inokuchi, Junichi, Akira Yokomizo, Naotaka Nishiyama, Hiroshi Kitamura, Masatoshi Eto, Hiroyuki Nishiyama, and Yoshihiko Tomita. "Perioperative therapies for urological cancers." Japanese Journal of Clinical Oncology 50, no. 4 (March 2, 2020): 357–67. http://dx.doi.org/10.1093/jjco/hyaa013.

Full text

Abstract:

Abstract Although surgery with curative intent is critical for management of many localized cancers, multimodal therapy including neoadjuvant and adjuvant therapy has been introduced to increase the effectiveness of local control of surgery and prolong survival. However, strong evidence supporting the utility of such multimodal therapy is limited. The utility of perioperative chemotherapy has been extensively investigated in bladder cancer, and several randomized controlled trials have indicated the benefit of neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Regrettably, perioperative therapy for other urological cancers is controversial; therefore, no definitive conclusions have been drawn. Recently, the number of trials has rapidly increased due to the development of immune checkpoint inhibitors, used alone or in combination with other modalities. In this review, we summarize the current status and supporting evidence for perioperative therapies such as neoadjuvant and adjuvant therapies for urological cancers, including prostate cancer, urothelial cancer and renal cell carcinoma.

APA, Harvard, Vancouver, ISO, and other styles

45

Lupi, Alessandro, Andrea Rognoni, Chiara Cavallino, Gioel G. Secco, Maria D. Prando, Matteo Santagostino, Maurizio Lazzero, Ettore Cassetti, and Angelo S. Bongo. "Pharmacological Adjuvant Therapies in Primary Coronary Interventions: Bivalirudin." Cardiovascular & Hematological Agents in Medicinal Chemistry 11, no. 2 (April 1, 2013): 106–14. http://dx.doi.org/10.2174/1871525711311020006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Samuel, Evangeline, Maggie Moore, Mark Voskoboynik, Mark Shackleton, and Andrew Haydon. "An update on adjuvant systemic therapies in melanoma." Melanoma Management 6, no. 3 (November 1, 2019): MMT28. http://dx.doi.org/10.2217/mmt-2019-0009.

Full text

Abstract:

There is a global increase in the incidence of melanoma, with approximately 300,000 new cases in 2018 worldwide, according to statistics from the International Agency for Research on Cancer. With this rising incidence, it is important to optimize treatment strategies in all stages of the disease to provide better patient outcomes. The role of adjuvant therapy in patients with resected stage 3 melanoma is a rapidly evolving field. Interferon was the first agent shown to have any utility in this space, however, recent advances in both targeted therapies and immunotherapies have led to a number of practice changing adjuvant trials in resected stage 3 disease.

APA, Harvard, Vancouver, ISO, and other styles

47

Vining, Charles C., Darryl Schuitevoerder, and Kiran K. Turaga. "Ampullary adenocarcinoma: the current state of adjuvant therapies." Hepatobiliary Surgery and Nutrition 9, no. 5 (October 2020): 647–49. http://dx.doi.org/10.21037/hbsn.2019.11.37.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Gottula, Adam L., Andrew D. Barreto, and Opeolu Adeoye. "Alteplase and Adjuvant Therapies for Acute Ischemic Stroke." Seminars in Neurology 41, no. 01 (January 20, 2021): 016–27. http://dx.doi.org/10.1055/s-0040-1722720.

Full text

Abstract:

AbstractAcute ischemic stroke (AIS) is a time sensitive medical emergency and a leading cause of morbidity and mortality worldwide. Intravenous (IV) recombinant tissue plasminogen activator (IV alteplase) is currently the only proven effective medication for the treatment of AIS with promising adjuvant medications currently under investigation. Recent advances in endovascular thrombectomy have broadened therapeutic options in specific patient populations, with modern treatment strategies utilizing advanced imaging modalities to extend the window for treatment. In all cases, rapid treatment remains a priority. The future of IV alteplase and the changing standard for treatment of AIS remain unwritten with the increasing evidence for imaging selection for both endovascular thrombectomy and IV alteplase, while novel adjuncts are under investigation. In this article, we review the history of IV alteplase investigations for stroke, evidence for thrombectomy as an adjunct to IV alteplase, and the potential of novel adjuvant therapeutics currently under investigation.

APA, Harvard, Vancouver, ISO, and other styles

49

Sanchez, Sabrina, and Jose Trevino. "Current Adjuvant and Targeted Therapies for Pancreatic Adenocarcinoma." Current Medicinal Chemistry 15, no. 17 (July 1, 2008): 1674–83. http://dx.doi.org/10.2174/092986708784872348.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Adjuvant Therapies in Women with Early Breast Cancer." Drugs & Therapy Perspectives 2, no. 11 (December 1993): 14–16. http://dx.doi.org/10.2165/00042310-199302110-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Adjuvant therapies'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles